Pharmamarketeer

European Commission approves new indication for Dupixent in chronic rhinosinusitis with nasal polyposis

The European Commission (EC), approved a new indication for Dupixent (dupilumab) in chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add─on therapy with intranasal corticosteroids

Medhc-fases-banner
Advertentie(s)